Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2013 Mar;14(4):475-88. doi: 10.1517/14656566.2013.765858. Epub 2013 Jan 29.

Lenalidomide in lymphomas and chronic lymphocytic leukemia.

Author information

1
Continuum Cancer Centers of New York, St. Lukes-Roosevelt and Beth Israel Medical Center, Leukemia Program, 1000 10th Ave, Ste. 11C-02, New York, NY 10019, USA. pwiernik@aol.com

Abstract

INTRODUCTION:

Lenalidomide , a thalidomide analog, is representative of a new class of antineoplastic drugs which has been especially effective in certain hematologic malignancies such as myeloma and myelodysplasia. Lenalidomide has anti-inflammatory, anti-angiogenic and immunomodulatory properties, and targets tumor cells by direct cytotoxicity and, indirectly by interfering with several components of the tumor microenvironment [1]. Lenalidomide retains antitumor activity equal to or greater than the parent compound, thalidomide, but with less toxicity [2].

AREAS COVERED:

This paper summarizes what is known about the mechanisms of action of lenalidomide, and recent clinical results in lymphoma and chronic lymphocytic leukemia. A literature review was accomplished by searching the PubMed database for papers in English. Publications from 2000 through November 2012 were analyzed. Search terms used were lenalidomide, lymphoma, chronic lymphocytic leukemia, and Hodgkin's lymphoma. A manual search of conference proceedings from the previous 5 years of the American Society of Clinical Oncology, American Society of Hematology, America Association of Cancer Research, and the European Hematology Association was also conducted. Relevant references in chosen papers were also considered.

EXPERT OPINION:

The data suggest that lenalidomide will play a major role in the management of certain lymphoid neoplasms such as B-cell lymphoma, chronic lymphocytic leukemia and, perhaps, T-cell lymphoma.

PMID:
23356486
DOI:
10.1517/14656566.2013.765858
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center